April 20th, 2007
Vitespen (Oncophage®), Promising Brain Tumor Vaccine
A brain tumor vaccine known as vitespen (trademarked as Oncophage®) has been found effective in stimulating the patient’s immune system to attack the tumor cells (tumor-specific immune response) in glioma.
The clinical trial being conducted at the University of California, San Francisco (UCSF) Brain Tumor Research Center tested patients that all had recurrent, high-grade glioma who […]
Recent Comments